气候变化领域集成服务门户(CCPortal): Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study

CCPortal

DOI	10.2147/IDR.S423725
	Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
	Zhao, Xiang; Cheng, Yuan; Zhang, Meng; Qianda, Bianba; Zhouma, Baima; Yangzhen, Bianba; Zheng, Yao; Zhang, Shuo; Zhao, Huiying
发表日期	2023
ISSN	1178-6973
起始页码	6053
结束页码	6060
卷号	16
英文摘要	Background: Nirmatrelvir-ritonavir, also known as paxlovid, is a widely used antiviral drug against coronavirus disease 2019 (COVID-19). Azvudine, a drug previously used to treat human immunodeficiency virus-1, has also been used to treat COVID-19 in China. However, only a few clinical studies have evaluated the effects of azvudine. Additionally, studies comparing nirmatrelvirritonavir with azvudine have been limited in number. Methods: We carried out a retrospective case-control analysis at the Third People's Hospital of the Tibet Autonomous Region. Eighty-two eligible patients with COVID-19 who received azvudine treatment were included. A total of 145 control patients who received nirmatrelvir-ritonavir treatment were selected by propensity score matching for age, sex, the severity of disease, and initial cycle threshold values. A comparison of the nucleic acid test negative conversion time, the length of hospitalization, and mortality rate was conducted. Results: Overall, the mean nucleic acid test negative conversion time was comparable between the nirmatrelvir-ritonavir and azvudine groups (7.0 [11.0, 15.0] vs 9.0 [6.0, 12.0] days, P=0.064). However, for patients with mild COVID-19, the nucleic acid test negative conversion time was significantly shorter in the nirmatrelvir-ritonavir group than in the azvudine group (6.0 [5.0, 8.0] vs 8.0 [6.0, 11.0] days, P=0.029). The nirmatrelvir-ritonavir group and the azvudine group did not differ significantly in length of hospitalization (8.0 [5.5,10.5] vs 8.0 [5.0,10.0] days, P=0.378). Regarding the mortality rate, there were 4 (2.8%) deaths in the nirmatrelvir-ritonavir group and 3 (3.7%) in the azvudine group (P=0.706). Conclusion: Azvudine is generally as effective as nirmatrelvir-ritonavir, but for patients with mild COVID-19, nirmatrelvir-ritonavir could suppress the virus more rapidly. For those who cannot be treated with nirmatrelvir-ritonavir, azvudine might be an effective therapy for COVID-19.
关键词	nirmatrelvir-ritonavir azvudine COVID-19 clinical outcome high altitude
WOS研究方向	Infectious Diseases ; Pharmacology & Pharmacy
WOS记录号	WOS:001068292400001
来源期刊	INFECTION AND DRUG RESISTANCE
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/283084
作者单位	Xizang Minzu University; Peking University
推荐引用方式 GB/T 7714	Zhao, Xiang,Cheng, Yuan,Zhang, Meng,et al. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study[J],2023,16.
APA	Zhao, Xiang.,Cheng, Yuan.,Zhang, Meng.,Qianda, Bianba.,Zhouma, Baima.,...&Zhao, Huiying.(2023).Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.INFECTION AND DRUG RESISTANCE,16.
MLA	Zhao, Xiang,et al."Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study".INFECTION AND DRUG RESISTANCE 16(2023).